Associated Papers
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.
Betancor G et al.
Retrovirology, 2012
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Marcelin AG et al.
Antiviral Therapy, 2012
Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
Lai MT et al.
Antimicrobial Agents and Chemotherapy, 2010
Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
Xu H et al.
Antimicrobial Agents and Chemotherapy, 2009
Select a paper to view details